Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohns disease.
性状
Liquid
IC50 & Target[1][2]
CXCL10 (IP-10).
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Gupta RK, et al. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLoS One. 2021 Sep 28;16(9):e0257784. [2]. Asquith DL, et al. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):204-11.